For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $16.47 in the prior trading day, Takeda Pharmaceutical Co ADR (NYSE: TAK) closed at $16.33, down -0.85%. In other words, the price has decreased by -$0.85 from its previous closing price. On the day, 2.22 million shares were traded. TAK stock price reached its highest trading level at $16.398 during the session, while it also had its lowest trading level at $16.16.
Ratios:
Our goal is to gain a better understanding of TAK by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.38. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.65 whereas as Long-Term Debt/Eq ratio is at 0.61.
BofA Securities Upgraded its Neutral to Buy on March 16, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 09 ’25 when Lauren Rusckowski Duprey bought 29,619 shares for $14.22 per share.
Teresa Marie Bitetti bought 87,023 shares of TAK for $1,242,688 on Dec 05 ’25. On Dec 04 ’25, another insider, Giles Richard Platford, who serves as the President, Plasma-Derived Ther of the company, bought 58,421 shares for $14.31 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TAK now has a Market Capitalization of 54342172672 and an Enterprise Value of 4536383569920. As of this moment, Takeda’s Price-to-Earnings (P/E) ratio for their current fiscal year is 207.23, and their Forward P/E ratio for the next fiscal year is 26.31. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.61. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.74 while its Price-to-Book (P/B) ratio in mrq is 1.07. Its current Enterprise Value per Revenue stands at 1.027 whereas that against EBITDA is 3.985.
Stock Price History:
The Beta on a monthly basis for TAK is 0.05, which has changed by 0.27476776 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, TAK has reached a high of $16.48, while it has fallen to a 52-week low of $12.80. The 50-Day Moving Average of the stock is 10.48%, while the 200-Day Moving Average is calculated to be 11.00%.
Shares Statistics:
The stock has traded on average 2.75M shares per day over the past 3-months and 2402660 shares per day over the last 10 days, according to various share statistics. A total of 3.16B shares are outstanding, with a floating share count of 3.16B. Insiders hold about 0.00% of the company’s shares, while institutions hold 2.71% stake in the company. Shares short for TAK as of 1767139200 were 10385239 with a Short Ratio of 3.78, compared to 1764288000 on 11381864. Therefore, it implies a Short% of Shares Outstanding of 10385239 and a Short% of Float of 0.33000002.
Dividends & Splits
In the trailing 12 months, TAK’s forward annual dividend rate was 198.0, compared to 0.32 this year. Against a Trailing Annual Dividend Yield of 12.021858. The stock’s 5-year Average Dividend Yield is 4.67.
Earnings Estimates
Analysts are recommending an EPS of between $51.16 and $51.16 for the fiscal current year, implying an average EPS of $51.16. EPS for the following year is $109.66, with 1.0 analysts recommending between $109.66 and $109.66.
Revenue Estimates
6 analysts predict $1.2T in revenue. The current quarter. It ranges from a high estimate of $1.26T to a low estimate of $1.15T. As of. The current estimate, Takeda Pharmaceutical Co ADR’s year-ago sales were $1.14TFor the next quarter, 6 analysts are estimating revenue of $1.08T. There is a high estimate of $1.15T for the next quarter, whereas the lowest estimate is $1.03T.
A total of 15 analysts have provided revenue estimates for TAK’s current fiscal year. The highest revenue estimate was $4.58T, while the lowest revenue estimate was $4.45T, resulting in an average revenue estimate of $4.52T. In the same quarter a year ago, actual revenue was $580.36BBased on 15 analysts’ estimates, the company’s revenue will be $4.54T in the next fiscal year. The high estimate is $4.65T and the low estimate is $4.41T.
